VEEV Veeva Systemsdata gap · 84% coverage
Health Care · Health Care Technology · close $310.36 (2026-10-16) · latest quarter in EDGAR: 2026-07-31
Veeva Systems (VEEV) has a ThetaGrade House Rating of 61/100 (grade C), ranking #8 of 150 in Health Care. Its strongest pillars are balance sheet (87) and growth (65); its weakest is valuation (19). Data gap: 3 factors without usable data, so 84% of the method weight is covered. TTM revenue growth is 16.5% and operating margin 29.9%.
Data as of .
Data gap
No usable data for: Interest coverage, FCF margin, FCF yield. Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 84% of the full method weight is backed by data.
- Capex: not tagged for FY ending 2026-01-31 under standard XBRL tags - FCF data gap
Analyst sentiment
weight 7.5% (→8.6%) · 50| Consensus score (1–5) (4.3%) | derived | 41 |
| 90-day net rating shift (4.3%) | derived | 49 |
Growth
weight 30.83% (→35.2%) · 65| Revenue growth YoY (TTM) (14.1%) | 16.5% | 67 |
| EPS growth YoY (TTM) (14.1%) | 25.7% | 62 |
| Revenue acceleration (7.0%) | 1.3% | 65 |
Profitability
weight 18.5% (→21.1%) · 61| Operating margin (11.3%) | 29.9% | 87 |
| 4Q gross-margin change (9.8%) | -0.6% | 31 |
Balance sheet
weight 18.5% (→21.1%) · 87| Net debt / EBITDA (14.1%) | -1.75× | 91 |
| Current ratio (7.0%) | 5.46 | 79 |
| Interest coverage (0.0%)data gap | — | — |
Cash flow
weight 12.33% · no data · —| FCF margin (0.0%)data gap | — | — |
| FCF yield (0.0%)data gap | — | — |
Valuation
weight 12.33% (→14.1%) · 19| P/E (inverted) (7.0%) | 50.80× | 20 |
| EV/Sales (inverted) (7.0%) | 14.01× | 18 |
Technicals (EOD)
| RSI(14) | 71.2 |
| EMA 9 / 21 | 298.30 / 286.97 |
| 200-day SMA | 204.87 |
| Volume vs 20d avg | 1.03× |
| 20-day return | 17.7% |
Exit-rule monitor
No exit or watch rules triggered.
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Gross profit: GrossProfit · Operating income: OperatingIncomeLoss · D&A: none tagged (EBITDA = EBIT) · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like VEEV's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is VEEV's House Rating?
- VEEV scores 61 out of 100 (grade C) as of 2026-10-16, ranking #8 of 150 Health Care stocks we cover.
- What do analysts say about VEEV?
- ThetaGrade's analyst-sentiment pillar for VEEV scores 50/100 against its sector peers, which we read as mixed. This is our own derived score; we do not republish individual analyst ratings, counts or targets.
- When does VEEV report earnings next?
- We do not have a reliable estimate for VEEV's next earnings date (irregular SEC filing history); a rough window is 2026-11-05 to 2026-12-03. Check the company's investor-relations page.
- Is VEEV a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology